A prospective evaluation of lipoprotein-associated phospholipase A2levels and the risk of future cardiovascular events in women

Blake, Gavin J.; Dada, Nisha; Fox, Jacob H.; Manson, JoAnn E.; Ridker, Paul M.

doi:10.1016/s0735-1097(01)01554-6

Cited by 194 publications

(113 citation statements)

References 21 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…This bears further elucidation. The lack of correlation between Lp-PLA 2 activity and hsCRP is consistent with other studies (11)(12)(13)(14), suggesting that the two risk markers may have an additive effect on predicting cardiovascular risk for individual patients.…”

Section: Lp-pla 2 Variabilitysupporting

confidence: 90%

See 1 more Smart Citation

The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort

Persson

Nilsson²,

Nelson³

et al. 2007

Atherosclerosis

View full text Add to dashboard Cite

Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is an enzyme that is produced by inflammatory cells (macrophages, T-lymphocytes and mast cells) and hydrolyzes oxidized phospholipids in LDL. Several epidemiology studies indicate that Lp-PLA 2 appears to be an independent marker of cardiovascular risk. This study was conducted to define the distribution of Lp-PLA 2 in a large population-based cohort and to determine associations between Lp-PLA 2 and other risk factors for CVD. The study group consisted of participants from the Malmö Diet and Cancer study (1992)(1993)(1994). LpPLA 2 (activity and mass) was measured from samples obtained at baseline for 5,402 participants (3,167 women). A strong correlation was observed between LpPLA 2 activity and mass in this study (r=0.57). Highest correlations were observed between Lp-PLA 2 activity and LDL (r=0.45) and LDL/HDL ratio (r=0.54) and a strong inverse correlation to HDL (r=-0.31). The correlations between Lp-PLA 2 mass and lipids were not as strong as the correlation between activity and lipids.LpPLA 2 activity and mass were correlated with increased ultrasound determined carotid intima-media thickness. We conclude that LpPLA 2 is strongly correlated with several cardiovascular risk factors, especially lipid fractions, and with the degree of carotid artery atherosclerosis. However, the measured variables accounted for only 19% and 35% of the variation in Lp-PLA 2 mass and activity respectively. cardiovascular disease, epidemiology, Lp-PLA 2 , risk factor 3 INTRODUCTION

show abstract

Section: Lp-pla 2 Variabilitysupporting

confidence: 90%

“…Recent epidemiology studies have examined the role of Lp-PLA 2 in predicting incident cardiovascular events (11)(12)(13)(14)(15). The majority of these studies have demonstrated that elevated Lp-PLA 2 (mass or activity) is an independent predictor of future events.…”

Section: Introductionmentioning

confidence: 99%

The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort

Persson

Nilsson²,

Nelson³

et al. 2007

Atherosclerosis

View full text Add to dashboard Cite

show abstract

“…Compared to hs‐CRP, Lp‐PLA2 has the advantage of being a more specific marker for cardiovascular risk 7. However, epidemiological studies conducted in different populations have found inconsistent results regarding whether Lp‐PLA2 can be used as a predictor of atherosclerosis 10. This controversy has fuelled the search for more effective prediction methods for cardiovascular disease.…”

Section: Introductionmentioning

confidence: 99%

Association between high‐sensitivity C‐reactive protein, lipoprotein‐associated phospholipase A2 and carotid atherosclerosis: A cross‐sectional study

Liu

Yao

Wang

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

High‐sensitivity C‐reactive protein (hs‐CRP) and lipoprotein‐associated phospholipase A2 (Lp‐PLA2) have been reported to be independent predictors of atherosclerosis. However, whether the combination of these two markers can improve the prediction of atherosclerosis is unknown. This study aimed to evaluate the association between combining hs‐CRP and Lp‐PLA2 and predicting carotid atherosclerosis. A total of 1982 participants aged ≥40 years were included in this study. Hs‐CRP and Lp‐PLA2 were measured by a high‐sensitivity nephelometry assay and quantitative sandwich enzyme‐linked immunosorbent assay, respectively. Ultrasonography was performed on the bilateral carotid arteries to evaluate stenosis and plaques. Multivariable logistic regression models were used to analyse the association between the combination of the hs‐CRP and Lp‐PLA2 levels and carotid plaques and stenosis. A total of 1579 (79.7%) and 181 (9.1%) subjects had carotid plaques and carotid stenosis, respectively. The group with high hs‐CRP and Lp‐PLA2 levels had the highest prevalence of carotid plaques (90.6%) and stenosis (20.8%). A significant association was found between high hs‐CRP and Lp‐PLA2 levels and carotid stenosis (adjusted odds ratio [OR]: 2.39; 95% confidence interval [CI]: 1.13‐5.09), but this combination was not associated with carotid plaques (OR: 2.62, 95% CI: 0.93‐7.38). The results suggested that the combination of hs‐CRP and Lp‐PLA2 were better predictors than either protein alone with regard to carotid atherosclerosis.

show abstract

“…For example, Packard, Caslake and their colleagues have described a positive association between plasma Lp-PLA2 levels and incidence of coronary heart disease in case-controlled studies among males in Scotland Packard et al 2000). A similar association between plasma Lp-PLA2 mass and coronary heart disease has been observed in Caucasian females (Blake et al 2001).…”

Section: Discussionmentioning

confidence: 82%

Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients

Ishihara¹,

Iwasaki²,

Nagano³

et al. 2004

J Hum Genet

View full text Add to dashboard Cite

Plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor (PAF) acetylhydrolase (PAF-AH), is a member of the serine-dependent class of A2 phospholipases that hydrolyze sn2-ester bonds of fragmented or oxidized phospholipids at sites where atherosclerotic plaques are forming. Most circulating Lp-PLA2 is bound to lowdensity lipoprotein (LDL) particles in plasma and the rest to high-density lipoprotein (HDL). Deficiency of Lp-PLA2 is a predisposing factor for cardiovascular diseases in the Japanese population. We describe here two novel mutations of the gene encoding Lp-PLA2, InsA191 and I317N in Japanese subjects. The first patient, with partial Lp-PLA2 deficiency, was heterozygous for the InsA191 mutation; macrophages from this patient secreted only half the normal amount of Lp-PLA2 in vitro. The other patient, who showed complete Lp-PLA2 deficiency, was a compound heterozygote for the novel I317N mutation and a common V279F mutation; macrophages from that patient failed to secrete any Lp-PLA2. Measurement of Lp-PLA2 mass, activity and Western blotting verified impaired production and secretion of the enzyme after transfection of mutant construct into COS-7 cells. These results indicated that both novel mutants, InsA191 and I317N, impair function of the Lp-PLA2 gene.

show abstract

A prospective evaluation of lipoprotein-associated phospholipase A2levels and the risk of future cardiovascular events in women

Abstract: In contrast to prior data among hyperlipidemic men, the current data suggest that Lp-PLA(2) is not a strong predictor of future cardiovascular risk among unselected women.

Cited by 194 publications

References 21 publications

The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort

The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort

Association between high‐sensitivity C‐reactive protein, lipoprotein‐associated phospholipase A2 and carotid atherosclerosis: A cross‐sectional study

Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients

Contact Info

Product

Resources

About